Meningococcal Infections — Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
Citation(s)
Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia.